Two failed cancer studies this week provided a fresh reminder how little researchers and clinicians understand about immunotherapy’s vagaries: why it works for some people and not for others.
The results, in lung cancer and head-and neck cancer, add to recent... Read more »
Austin and San Antonio—Technology, of course, gives us all greater access to information than ever before. In the context of security, however, that’s often a big problem.
Companies have historically set up boundaries around the information they’re trying to protect—firewalls... Read more »
Despite all the great progress made harnessing the immune system to fight cancer, there is still much work to be done to maximize its potential. The latest evidence: disappointing results today from a roughly 1,100-patient study called “Mystic,” a highly anticipated... Read more »
After weeks of hints, rumors, and speculation, it’s now official: Foxconn, the world’s largest contract manufacturer, said it will invest $10 billion over the next three years to build an enormous plant in Southeastern Wisconsin and make electronics displays there.
President... Read more »
A federal judge ruled earlier this week that Apple must pay an additional $272 million to the organization that manages patents and licensing of intellectual property for the University of Wisconsin-Madison for infringing one of its patents, according to court documents.... Read more »
Dallas—Prodea Systems, a suburban Dallas maker of Internet-connected software, has acquired a California-based competitor, Arrayent.
“There are more and more services and systems and devices that would become smart and try to deliver information,” Anousheh Ansari, Prodea’s co-founder and CEO,... Read more »
For filmmakers and game designers, virtual reality technology has created a quirky playground of the imagination where characters can actually run into themselves at a bar, and where viewers’ eyebrows can be made invisible to widen their views of the sky.... Read more »
Genomics startups are increasing in number and quality, so much so that three-year-old Illumina Accelerator has expanded with its latest class to accommodate five of them. Xconomy got an early look at the specialty accelerator’s sixth cohort, which includes a company... Read more »
Convoy, a startup trying to modernize the way truck drivers connect with customers, just got a $62 million boost from investors including the Y Combinator Continuity Fund and Microsoft co-founder Bill Gates.
The Seattle startup, which makes technology that would automate... Read more »
San Diego’s Effector Therapeutics, a five-year-old cancer drug developer, has raised $38.6 million in new venture capital funding. The Series C financing, led by Pfizer Venture Investments, brings total funding for Effector to about $150 million, CEO Steve Worland said late... Read more »
The first immunotherapy approved in the U.S. to treat head and neck cancer has failed a big test, but it’s unclear if the FDA will exercise its right to pull it from the market.
Merck (NYSE: MRK) announced late Monday... Read more »
Nektar Therapeutics has been buoyed of late by the progress of a potential pain drug, but another, much earlier program has caught the eye of Eli Lilly, which has agreed to write the San Francisco company a $150 million check to... Read more »
Does your genetic code contain information that can help you lose weight?
It’s a serious question in science, and in business. Now, the makers of Lose It aim to find out. The nine-year-old mobile app—from Boston-based parent company FitNow—was early... Read more »